{"name": "Transdel Pharmaceuticals",
 "permalink": "transdel-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/transdel-pharmaceuticals",
 "homepage_url": "http://www.transdelpharma.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@transdelpharma.com",
 "phone_number": "858-457-5300",
 "description": "",
 "created_at": "Thu Oct 28 07:03:25 UTC 2010",
 "updated_at": "Thu Oct 28 07:03:24 UTC 2010",
 "overview": "\u003Cp\u003ETransdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company\u0026#8217;s innovative-patented Transdel\u00e2\u201e\u00a2 cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel\u00c2\u00ae, the Company\u0026#8217;s lead pain product candidate, has completed a Phase 3 clinical trial and utilizes the Transdel\u00e2\u201e\u00a2 technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlying tissues where the drug exerts its well-known anti-inflammatory and analgesic effects. The Company intends to leverage its Transdel\u00e2\u201e\u00a2 platform technology to expand and create a portfolio of topical products for a variety of indications. The Company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       39],
      "assets/images/resized/0010/7625/107625v1-max-150x150.png"],
     [[225,
       59],
      "assets/images/resized/0010/7625/107625v1-max-250x250.png"],
     [[225,
       59],
      "assets/images/resized/0010/7625/107625v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "John",
      "last_name": "N. Bonfiglio",
      "permalink": "john-n-bonfiglio",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "4275 Executive Square",
    "address2": "Suite 230",
    "zip_code": "92037",
    "city": "La Jolla",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}